Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TRPC5 | Q9UL62 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234639 | 0.91 | MAPT (0.55) | TP53MAPTLMNAGAAHTT | |
| SCHEMBL3229938 | 0.89 | MAPT (0.52) | TP53MAPTLMNAGAAHTT | |
| SCHEMBL3238173 | 0.89 | MAPT (0.55) | TP53MAPTLMNAADORA3SMN1; SMN2 | |
| SCHEMBL3229109 | 0.86 | ADORA2A (0.59) | MAPTLMNAHTTADORA3 | |
| SCHEMBL13940720 | 0.86 | MAPT (0.51) | TP53MAPTLMNAGAAHTT | |
| SCHEMBL13940860 | 0.86 | MAPT (0.49) | TP53TRPC5MAPTTRPC4LMNA | |
| SCHEMBL16028537 | 0.86 | TRPC5 (0.63) | TP53TRPC5MAPTTRPC4KCNH2 | |
| SCHEMBL3110981 | 0.86 | MAPT (0.48) | TP53MAPTLMNAGAAHTT | |
| SCHEMBL3236349 | 0.85 | MAPT (0.50) | TP53MAPTLMNAGAAHTT | |
| SCHEMBL3240004 | 0.85 | MAPT (0.56) | TP53MAPTLMNAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | TP53 4885/4885TRPC5 271/4885MAPT 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.